Clinical Trial News and Research

RSS

New technique effective in jumpstarting defective immune systems against many diseases

In a study published in Nature Medicine, Loyola researchers report on a promising new technique that potentially could turn immune system killer T cells into more effective weapons against infections and possibly cancer.

26 Feb 2012

Certara acquires Simcyp

Simcyp Limited announces its acquisition by Certara, a leading provider of drug discovery and development software and scientific consulting services.

24 Feb 2012

SANUWAVE, CAN-med Healthcare enter distribution agreement for dermaPACE device

SANUWAVE Health, Inc. has entered into a two-year exclusive distribution agreement with CAN-med Healthcare, a division of IMP Group Limited, to distribute the Company's dermaPACE device throughout Canada.

24 Feb 2012

Cyberonics third quarter net sales increase 16% to $54.5 million

Cyberonics, Inc. today announced results for the quarter ended January 27, 2012.

24 Feb 2012

FDA clears invendo medical's new C20 colonoscopy system

invendo medical announced today that the company received 510(k) clearance by the U.S. Food and Drug Administration of the company's new C20 colonoscopy system including the SC20 single-use colonoscope.

24 Feb 2012

Researchers begin clinical trial of first visceral leishmaniasis vaccine

"Researchers say they've developed the first vaccine for visceral leishmaniasis (VL) -- a disease that affects 500,000 people each year and has been called the 'parasitic version of HIV,'" although the diseases are unrelated, U.S. News reports.

24 Feb 2012

Ipsen, Active Biotech report data from tasquinimod Phase II study on CRPC

Active Biotech's and Ipsen's castrate resistant prostate cancer project, TASQ, will be presented at the 27th Annual EAU Congress held in Paris on 24-28 February 2012.

24 Feb 2012

NHS approves new rheumatoid arthritis drug RoActemra

RoActemra, which is the first innovation in the field for ten years, is being recommended for patients who have failed on standard treatments. It is the first time RoActemra has been approved for NHS patients in England and Wales with moderate to severe rheumatoid arthritis who are at an early stage in the disease. The drug has been available for early use in Scotland for two years.

23 Feb 2012

New CETP blockers continue to show promise as viable heart drugs

Mindful of lessons from a failed heart drug that cost $800 million to develop, drug companies are taking another shot at new medications that boost levels of so-called "good cholesterol," which removes cholesterol from the body.

23 Feb 2012

U-M Cardiovascular Center now offers Edwards aortic valve replacement

As the population ages, more Americans will be susceptible to aortic stenosis, but not all patients can tolerate surgery to treat it. Select U.S. hospitals are now performing minimally invasive procedures called transcatheter aortic valve replacement, or TAVR, to replace a patient's diseased aortic valve without heart bypass or open heart surgery.

From Medtronic 23 Feb 2012

Varenicline improves walking ability in patients with SCA3

A nicotinic drug approved for smoking cessation significantly improved the walking ability of patients suffering from an inherited form of ataxia, reports a new clinical study led by University of South Florida researchers.

23 Feb 2012

Enrollment complete in Onyx Phase 3 ASPIRE trial for relapsed multiple myeloma

Onyx Pharmaceuticals, Inc. today announced that it has reached the target enrollment in the ASPIRE trial, a Phase 3 international clinical trial evaluating carfilzomib in combination with lenalidomide (Revlimid) and low dose dexamethasone in patients with relapsed multiple myeloma.

23 Feb 2012

MannKind net loss for 2011 decreases to $160.8 million

MannKind Corporation today reported financial results for the fourth quarter and year ended December 31, 2011.

23 Feb 2012

IDRI launches LEISH-F3 + GLA-SE Phase 1 trial for kala-azar

The first clinical trial of a new vaccine for visceral leishmaniasis (VL) has been launched by the Infectious Disease Research Institute (IDRI), a Seattle-based nonprofit that develops products to prevent, detect, and treat diseases of poverty. The Phase 1 trial is taking place in Washington State, with a companion Phase 1 trial planned in India, an epicenter of the disease.

23 Feb 2012

First use of HeartLight Endoscopic Ablation System to treat atrial fibrillation

For the first time in a new U.S. clinical trial, researchers at Mount Sinai School of Medicine have used the HeartLight Endoscopic Ablation System (EAS) to correct abnormal electrical signals inside the heart of a patient affected by atrial fibrillation (AFib), one of the nation's most common heart ailments.

22 Feb 2012

Simple blood test may provide early detection of cancer

A simple blood test is being developed by researchers at Ben-Gurion University of the Negev (BGU) and Soroka University Medical Center in Beer-Sheva, Israel that may provide early detection of many types of cancer.

22 Feb 2012

Insulin production may persist for decades after onset of type 1 diabetes

Massachusetts General Hospital (MGH) research has found that insulin production may persist for decades after the onset of type 1 diabetes. Beta cell functioning also appears to be preserved in some patients years after apparent loss of pancreatic function. The study results appear in the March issue of Diabetes Care.

22 Feb 2012

Combination of gemcitabine and MRK003 kills pancreatic cancer cells

Cancer Research UK scientists have revealed how a combination of two very different drugs - currently being tested in clinical trials - amplifies the destruction of pancreatic cancer cells, according to research published in the Journal of Experimental Medicine, today.

22 Feb 2012

FDA to review rejected weight loss drug Qnexa

The weight loss pill Qnexa has been once rejected by the FDA over safety concerns. But this Wednesday it will get a second chance before an FDA advisory committee. Qnexa maker Vivus Inc. hopes something might come out of this second chance. The company will be submitting new safety data from patients who took Qnexa for a second year after completing a one-year clinical trial.

21 Feb 2012